Moleculin Biotech (MBRX)

• Market cap: $23M
• 1 day: 3.01%
• 5 days: -5.02%
• 1 month: -12.19%
• 3 months: -25.89%
• 6 months: -56.09%
• Year to date: -73.71%
• 1 year: -82.1%
• 5 years: -99.24%
• 10 years: -99.94%
• Sector: Healthcare
• Industry: Biotechnology

About: Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Employees: 17